// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.

Reinhard Dummer - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dabrafenib Mesylate

JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.

Ramez Nassef Eskander - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

Bevacizumab

The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.

Sant P. Chawla - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Soft tissue sarcoma

Trabectedin

Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.

Piotr Rutkowski - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Modeling of prognostication based on genomic expression in the tumor microenvironment of muscle invasive urothelial carcinoma via machine learning.

Sunyoung S. Lee - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Immune-related adverse event (irAE) education, self-efficacy, and potential irAE experiences in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).

Urvi Mujumdar - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Characterizing the T cell repertoire in lung squamous cell premalignancy and its association with lesion outcome.

Asaf Maoz - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Carbetimer

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.

Nicolas Guibert - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Nivolumab

Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice.

David James Pinato - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment.

Paul B. Robbins - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

Magnus Lindskog - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Intuvax

Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC).

John B. A. G. Haanen - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Inlyta

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).

Reinhard Dummer - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

PDR001

A network meta-analysis of immunotherapy-based regimens for first-line treatment of advanced non-squamous non-small cell lung cancer.

Himani Agg - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pemetrexed

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.

Georgina V. Long - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

PDR001

PLASMA SODIUM CONCENTRATION AND THE RISK OF CARDIOVASCULAR DISEASE ( A LARGE COMMUNITY-BASED COHORT STUDY )

Cole, N - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

RNASEQ STUDY OF SALT STRESS PATHWAYS IN RENAL TUBULE REVEALS INCREASED EXPERSSION OF HEAT SHOCK GENES INVOLVED IN SALT SENSITIVE HYPERTENSION

Graham, L - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

THE ROLE OF PMCA1 IN HYPERTENSION AND ARRHYTHMIA SUSCEPTIBILITY IN RELATION TO AGEING

Wilson, C - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

ARE YOU REALLY AS OLD AS YOUR ARTERIES? PREDICTING BIOLOGICAL AGE USING CARDIO-ANKLE VASCULAR INDEX AS A MARKER OF VASCULAR STIFFNESS

Kirkham, F - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PHASE II RANDOMIZED SHAM-CONTROLLED STUDY OF RENAL DENERVATION FOR SUBJECTS WITH UNCONTROLLED HYPERTENSION – WAVE IV

Schmieder, R.E - European Meeting on Hypertension and Cardiovascular Protection (ESH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved